glp-1 and hrt for perimenopause Are you navigating menopause while considering treatments? You're not alone in having questions. With so much conflicting information out there, it's crucial to distinguish between myths evidence-based facts. From hormone What I Got Wrong About

Your provider can offer additional support, adjust strategies as needed, and help you navigate challenges in maintaining your new weight

Pancreatic safety of incretin-based drugs-FDA and EMA assessment

Such OXM analogues hold promise for the treatment of obesity and independently support the findings with glucagon-based co-agonists

Different medications produce different degrees of gastric emptying delay, and individual responses vary significantly

[DOI] [PubMed] [Google Scholar] 94.Irimia J.M., Meyer C.M., Segvich D.M., Surendran S., DePaoli-Roach A.A., Morral N., Roach P.J

A further study presented at Digestive Disease Week 2025 of 993 patients found GLP-1RA to be associated with a statistically significant increase in clinical remission rates (HBI or Mayo score) at 3 months numerical at 6 and 12 months without an increase in side-effects